Breaking Finance News

GlaxoSmithKline PLC (LON:GSK) price target maintained at 1,800.00GBX, released a research note earlier today by Citigroup

Citigroup hold steady the target price of GlaxoSmithKline PLC (LON:GSK) at 1,800.00GBX indicating a possible upside of 0.07%.

On 9/30/2016, Exane BNP Paribas released a statement for GlaxoSmithKline PLC (LON:GSK) maintained the target price at 1,520.00GBX that suggested a downside of -0.07%.

Boasting a price of 1,681.75GBX, GlaxoSmithKline PLC (LON:GSK) traded 1.70% higher on the day. With the last stock price close up 9.68% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. GlaxoSmithKline PLC has recorded a 50-day average of 1,645.03GBX and a two hundred day average of 1,551.57GBX. Volume of trade was up over the average, with 8,905,847 shares of GSK changing hands over the typical 7,819,370

Performance Chart

GlaxoSmithKline PLC (LON:GSK)

With a total market value of 0 GBX, GlaxoSmithKline PLC has price-earnings ratio of 2,836.23 with a one year low of 1,277.25GBX and a one year high of 1,716.50GBX .

A total of 24 equity analysts have released a ratings update on GSK. Three equity analysts rating the company a strong buy, six equity analysts rating the company a buy, seventeen equity analysts rating the company a hold, two equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 1,577.33GBX.

Brief Synopsis About GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.